cis-Revumenib (cis-SNDX-5613) is an isomer of Revumenib. Revumenib (SNDX-5613) is a potent and specific Menin-MLL inhibitor with a binding K i of 0.149 nM and a cell based IC50 of 10-20 nM. Revumenib can be used for the research of MLL-rearranged (MLL-r) acute leukemias, including acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML) [1].
In Vivo, Revumenib shows in vivo plasma IC50 of 53 nM. Revumenib treatment provides significant survival benefit and leukemic control in aggressive MOLM-13 disseminated xenografts[1].
References:
[1]. A drug, SNDX-5613, to treat acute leukemia with a KMT2A translocation or an NPM1 mutation that has come back (relapsed) or has not gotten better with treatment (refractory).
In Vivo, Revumenib shows in vivo plasma IC50 of 53 nM. Revumenib treatment provides significant survival benefit and leukemic control in aggressive MOLM-13 disseminated xenografts[1].
References:
[1]. A drug, SNDX-5613, to treat acute leukemia with a KMT2A translocation or an NPM1 mutation that has come back (relapsed) or has not gotten better with treatment (refractory).